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Introduction: Juvenile hyaline fibromatosis and infantile systemic hyalinosis are variants of the same autosomal
recessive syndrome; hyaline fibromatosis syndrome, characterized by papulonodular skin lesions, gingival
hypertrophy, flexion contractures of joints, osteolytic bone lesions and stunted growth. Infantile systemic hyalinosis
is distinguished from juvenile hyaline fibromatosis by its more severe phenotype, which includes hyaline deposits in
multiple organs, recurrent infections and death within the first two years of life.
Hyaline fibromatosis syndrome is due to mutations of the gene-encoding capillary morphogenesis protein 2
(CMG2). Cases have been reported in different countries but to the best of our knowledge, this is the first reported
Moroccan patient with hyaline fibromatosis syndrome and carrying the CMG2 mutation.
Case presentation: We report the case of an eight-year-old Moroccan male patient with typical features of hyaline
fibromatosis syndrome: multiple recurring subcutaneous tumors, gingival hypertrophy, joint contractures and other
anomalies carrying a homozygous mutation in the CMG2 gene. The identification of the mutation in our patient
allowed us to do a presymptomatic diagnosis in our patient’s sister, a two-day-old newborn, who is carrying the
familial mutation in the heterozygous state. Early recognition of this condition is important for genetic counseling
and early treatment.
Conclusions: Hyaline fibromatosis syndrome might be underdiagnosed. Molecular diagnosis will help clinicians and
geneticists, firstly to conduct genetic counseling, prenatal diagnosis and early treatment, and secondly to gain
better understanding of the disease and genotype-phenotype correlations.
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Juvenile hyaline fibromatosis (JHF MIM 228600) and
infantile systemic hyalinosis (ISH MIM 236490) are
autosomal recessive conditions characterized by multiple
subcutaneous skin nodules, gingival hypertrophy, joint
contractures and hyaline deposition. The onset of clin-
ical manifestations of JHF is normally in the first three
to four months of life, and ISH typically manifests in the
first weeks to months of life. In both disorders, mental
development is normal.
In JHF, lesions may be nodular and/or papular skin le-
sions (on the face, neck and especially on retroauricular* Correspondence: imane_cj@yahoo.fr
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article, unless otherwise stated.and perinasal regions), large tumors (especially on the
scalp, trunk and limbs) and perianal plaques or nodules.
Gingival hypertrophy is common, impairing eating. Bone
manifestations include osteolytic lesions (especially in
the distal phalanges and metaphyses), cortical thinning
and generalized osteopenia. There are reports of sco-
liosis, macrocephaly and reduced weight and height. The
diagnosis is confirmed by the demonstration of hyaline
deposition in the dermis. The origin and nature of the
amorphous hyaline material have been unclear, but it ap-
pears to be principally composed of glycoproteins and
glycosaminoglycans [1].
In ISH, in addition to cutaneous lesions, there is articu-
lar contracture, gingival hypertrophy and bone abnor-
malities, and the skin is thick, with hyperpigmentation
over bone prominences. The disease progresses with
persistent diarrhea, recurrent infections and death within
the first two years of life. This disorder shares manyed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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birth or within the first few months, with painful, swollen
joint contractures and livid red hyperpigmentation over
bony prominences. Histologically, ISH is also charac-
terized by hyaline deposition, but this is more widespread
than in JHF and can affect many tissues including
skin, skeletal muscle, cardiac muscle, gastrointestinal tract,
lymph nodes, spleen, thyroid and adrenal glands [2].
JHF and ISH are two variants of the same disease, now
jointly called hyaline fibromatosis syndrome (HFS), this
term was first introduced by Nofal et al. [3-5]. The first
medical case of HFS was reported in 1903 [6]. The dis-
ease was first called molluscum fibrosum, then juvenile
hyaline fibromatosis and infantile systemic hyalinosis [7],
and since it was realized that these were different mani-
festations of the same disease, the unifying term hyaline
fibromatosis syndrome has been adopted [5]. Some 150
medical cases have been reported, showing no geograph-
ical or ethnic predisposition. HFS is due to mutations of
the gene-encoding capillary morphogenesis protein 2
(CMG2) at 4q21. CMG2 is a transmembrane protein
that is induced during capillary morphogenesis and that
binds laminin and collagen IV via a von Willebrand fac-
tor type A (vWA) domain.
Here we describe the first Moroccan HFS patient with
typical features characteristic of the syndrome. This pa-
tient carries a homozygous mutation of the CMG2 gene.
Case presentation
An eight-year-old Moroccan male patient was referred to
our center for a medical genetics consultation because of
the associated presentation of a dysmorphic facies and
multiple malformations. He was born to a healthy consan-
guineous couple, a 27-year-old mother and 40-year-old
father. There was a family history of one sister dying at
the age of three years with the same symptoms as her
brother without a clear diagnosis. The pregnancy was not
medically followed, but it was reported to be without
complications. At birth, he weighed 2800g, he had a
length of 52cm and a head circumference of 36cm. DuringFigure 1 Papular and nodular skin lesions, hyperpigmentation and jothe first month of life, he appeared to progress normally
in his development. A clinical examination at eight-years-
old showed a delay in growth development with a weight
of 15kg (–3 standard deviation), height of 80cm (–4 stan-
dard deviation) and an Occipital Frontal Circumference of
52cm (mean). He presented with joint contractures, pain-
ful diffusely thickened skin, hyperpigmentation over joints,
papular and/or nodular skin lesions and gingival hyper-
trophy (Figure 1). His cognitive development was normal.
His skin biopsy showed hyaline material accumulation in
the dermis.
Based on the clinical pictures and the histological test,
a diagnosis of hyaline fibromatosis syndrome grade 2
(HFS) was made. The child was managed conservatively
with supportive care given with pain relief, physio-
therapy, antimicrobial therapy and dietary modifications.
Informed consent was obtained from the child’s
parents prior to implementation of the molecular assay.
Peripheral blood was collected from the affected child
and his parents.
DNA was extracted from whole blood by conventional
methods. Because there is a known hotspot region in
exon 13, we amplified this exon using the following
primers: CMG2-13F: GCAAGCTTCAGTGAGGGACT
and CMG2-13R: GCATGGTATCTGCATTTGGA.
Sequencing of the exon 13 of the CMG2 gene revealed
a homozygous deletion in the exon 13 (c.1074delT;
p.A359HfsX50; Figure 2B), confirming the diagnosis of
HFS. The parents were extensively counseled regarding
the diagnosis and its grave outcome.
We searched for this mutation in the child’s sister, a
two-day-old newborn, who was found to be carrying the
familial mutation in the heterozygous state (Figure 2C).Discussion
Our case report describes a child who presented with
the typical clinical and anatomopathological features of
HFS with a progressive and disabling joint pain and
contractures.int contractures.
Figure 2 Electrophoregrams from family with ISH showing
wild-type (A) and mutant CMG2 sequence (B, C). HFS, Hyaline
fibromatosis syndrome.
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tion by Landing and Nadorra in 1986 [8]. This disorder
is rare, but it has been recognized in families of various
ethnic backgrounds on multiple continents [9]. One re-
port described multiple cases in the Arab population
[10], reflecting the presence of consanguinity. HFS is an
autosomal recessive disorder that results from mutations
in the anthrax toxin receptor 2 gene, ANTXR2 [10]. The
gene ANTXR2 or CMG2 encodes a type I membrane
protein that is expressed ubiquitously in the human
body [11], with the notable exception of the brain.
CMG2 is a type I membrane protein involved in the
homeostasis of the extra cellular matrix. This gene was
identified as the second receptor for the anthrax toxin.
It was found to be responsible for anthrax infection [12]
as well as for HFS [13].
The exact cellular role of the protein CMG2 is poorly
understood. The best-characterized role of CMG2 is, how-
ever, to be the receptor for the anthrax toxin [14,15].
CMG2 enables the anthrax toxin to bind to cells, be inter-
nalized and reach the cytosol where it exerts its toxic
function. However, several observations have discussed a
role in angiogenesis. CMG2 was originally identified as a
gene upregulated in endothelial cells, which play a role in
the three-dimensional collagen matrices [12]. In mice,
CMG2 was found to be expressed in endothelial cells inthe lung, intestine, skin, on smooth muscle cells and in
the vascular endothelium [15].
Anthrax toxin receptor 2 is a protein of 488 amino acids
which harbors an extracellular von Willebrand A domain
(vWA), followed by an uncharacterized immunoglobulin-
like domain [15], a transmembrane domain and finally a
148 residue cytosolic tail [14]. The vWA was shown to
bind collagen IV and laminin [12]. It contains a metal ion-
dependent adhesion site motif with which they interact
with extracellular matrix proteins such as collagens. The
second extracellular domain of CMG2 is predicted to have
an immunoglobulin (Ig) fold [14,15]. Little is known about
the transmembrane domain of CMG2, and no structural
studies are currently available for the cytosolic tail of
CMG2. However, it has been shown that the Ig-like do-
main contains two disulfide bonds essential for proper
ANTXR2 folding in the endoplasmic reticulum [15], and
the cytosolic tail plays a role in the interaction with mul-
tiple partners during endocytosis. It also contains multiple
posttranslational modification sites such as palmitoylation
[15], phosphorylation [16] and ubiquitination [16].
More than 150 cases of HFS have been reported and
some 34 different mutations, from exon 1 to exon 15, have
been identified [14]. Among them, exon 13 is a hotspot
for frameshift mutations, which include insertion of one
or two bases (c.1073-1074insC and c.1073-1074insCC)
and deletion of one base (c.1074delT). Yan et al. have
shown that these three frameshift mutations represent
approximately 60% of all the pathogenic alleles [17]. The
frequency of insertions and deletions at positions 1073 to
1074 is likely due to its proximity to a low complexity,
GC-rich, region encoding a stretch of proline residues that
could constitute a vulnerable site for errors during DNA
replication.
Little is known about the consequences of mutations
in the CMG2 gene and especially in exon 13. The frame-
shift mutation c.1074delT leads to a premature stop
codon. The mutated delT gene encodes for the ANTXR2
protein has modified and shorter cytosolic tails of 66
amino acids compared with the 148 residue wild-type
ANTXR2 tail [17]. Indeed, not only is the site of a muta-
tion is crucial but the nature of the insertion and/or de-
letion, for example the change in the reading frame.
Therefore, it is important to perform genotype-pheno-
type correlation at the mRNA, protein, and functional
levels, and to analyze the molecular consequences of the
specific mutations in exon 13 of the CMG2 gene in order
to evaluate the potential therapeutic targets. Deuquet
et al. showed that the frameshift mutations in exon 13
lead to a decrease in the mRNA levels of CMG2, presum-
ably due to degradation via the nonsense-mediated mRNA
decay pathway [14]. Yan et al. have shown that c.1073-
1074insCC and c.1074delT mutations lead to defects not
only at the mRNA level but also at the protein-folding
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rescue ANTXR2 expression levels, leaving gene re-
placement as the only treatment possibility in these pa-
tients [17].
Our patient is carrying the mutation c.1074delT in the
homozygous state; this single nucleotide deletion in exon
13 was previously reported in patients with different
ethnic origins. It was described in a homozygous state in
a Kuwaiti family with ISH [3], and in a compound he-
terozygous state with JHF phenotype in an Italian family
[18]. This mutation modifies the open reading frame by
a frameshift leading to a change in the cytosolic tail of
the protein and a premature stop. This mutation is often
associated with a severe form of HFS; a survey of the
literature indicates that patients carrying the c.1073-
1074insCC or c.1074delT mutations always suffer from
the severe form of the disease, while more moderate
symptoms are reported for patients with the c.1073-
1074insC mutations.
A symptomatic treatment is recommended for HFS.
Nonsteroidal anti-inflammatory drugs and opiates help
to control pain. When passive movement of joint con-
tractures is painful, physiotherapy should be carried out
with care. Early surgical excision of the dermal tumors
is indicated for functional and esthetic improvement.
Complete excision should be performed in the early
phase of tumor development. An intralesional steroid in-
jection may reduce the size of early lesions. A partial
gingivectomy may be helpful to treat gingival over-
growth. Oral D-penicillamine has been used in some
cases with apparent improvement in joint mobility and
flexibility [9].
Cases have been reported from different countries all
over the world. To the best of our knowledge, this is the
first reported Moroccan patient with this HFS. Here, we
describe the clinical and genetic data of a Moroccan
patient with HFS. This diagnosis allowed us to provide
appropriate management for the patient, to conduct
genetic counseling with his family, to do presymptomatic
diagnosis and to enrich genetic data on the Moroccan
population. We suspect that the prevalence of HFS in
Morocco could be high, especially with the high rate of
consanguinity in Morocco (15.25%); this leads to an in-
creased level of autosomal recessive diseases [19]. The
HFS disease could well be underdiagnosed, supported by
the fact that our patient had one sister who passed away
in infancy without a precise diagnosis.
Conclusions
HFS is still a poorly understood disease of a particular
biology and raises a problem of treatment. However, the
major benefit in identifying pathogenetic mutations in
individual cases with HFS is to conduct genetic coun-
seling, prenatal diagnosis and provide early treatment.Consent
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